Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Jan-Paul Bohn"'
Autor:
Lena Prantl, Philipp Heider, Lisa Bergmeister, Katharina Calana, Jan-Paul Bohn, Dominik Wolf, Zoltan Banki, Andreas Bosch, Maximilian Plach, Georg Huber, Silke Schrödel, Christian Thirion, Heribert Stoiber
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Antibody-mediated complement-dependent cytotoxicity (CDC) on malignant cells is regulated by several complement control proteins, including the inhibitory complement factor H (fH). fH consists of 20 short consensus repeat elements (SCRs) with specifi
Externí odkaz:
https://doaj.org/article/fd7bcb08e40f4d34bd49d48974f1b01c
Autor:
Florian Simon, Rudy Ligtvoet, Thomas Noesslinger, Jan-Paul Bohn, Julia Von Tresckow, Rüdiger Liersch, Tobias Gaska, Kathleen Jentsch-Ullrich, Michael Koenigsmann, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Karl-Anton Kreuzer, Sandra Robrecht, Anna-Maria Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael Hallek, Barbara Eichhorst
Publikováno v:
HemaSphere, Vol 7, p e3844763 (2023)
Externí odkaz:
https://doaj.org/article/8a43f0f54e4c40a8b2e60240c8a0ce55
Autor:
Dai Chihara, Luuk Gras, Nienke Zinger, Nicolaus Kröger, Jiri Mayer, Jakob Passweg, Régis Peffault de Latour, Jenny Byrne, William Krüger, Jan-Paul Bohn, Uwe Platzbecker, Igor Wolfgang Blau, Francesca Bonifazi, Grzegorz Helbig, Andrew McDonald, Martin Mistrik, Mohamad Mohty, Ron Ram, Jaime Sanz, Carlos Vallejo Llamas, Robert J. Kreitman, Patrick J. Hayden, Donal McLornan, Olivier Tournilhac, Michel van Gelder, Ibrahim Yakoub-Agha
Publikováno v:
Haematologica, Vol 108, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/11382458eb3e4a7baeb266709043539f
Autor:
Jan-Paul Bohn, Anna Fiala, Sebastian Bachmann, Christian Irsara, Dominik Wolf, Clemens Feistritzer
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
The introduction of extended factor IX (FIX) products has significantly facilitated the treatment of hemophilia B patients. However, optimal perioperative management remains a topic of hot debate, particularly in surgeries with high bleeding risk. Fo
Externí odkaz:
https://doaj.org/article/1dbedcfcd39c4ab9adf9f3eaa0b864cf
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 15, p 7780 (2021)
Classic hairy cell leukemia (HCL) is a rare mature B-cell malignancy associated with pancytopenia and infectious complications due to progressive infiltration of the bone marrow and spleen. Despite tremendous therapeutic advances achieved with the im
Externí odkaz:
https://doaj.org/article/9f2885559104402788b14f346ed0ca6f
Autor:
Jan-Paul Bohn
Publikováno v:
memo - Magazine of European Medical Oncology. 15:53-57
SummaryThe treatment landscape of chronic lymphocytic leukemia (CLL) has shifted from chemotherapy-based approaches to targeted agents in the last decade. However, evolving drug resistance and accumulating toxicity remain challenges that still limit
Autor:
Jan-Paul Bohn
Publikováno v:
Memo. 15(2)
SummaryThe treatment landscape of chronic lymphocytic leukemia (CLL) has undergone profound change in recent years. Targeted therapies have outnumbered chemotherapy-based treatment approaches demonstrating superior efficacy and tolerability profiles
Autor:
Jan-Paul Bohn, Dominik Wolf
Publikováno v:
memo - Magazine of European Medical Oncology. 13:259-265
SummaryA deeper understanding of disease biology and the advent of targeted drugs have implemented chemotherapy-free treatment options in chronic lymphocytic leukemia (CLL). With consistently superior outcome data and good tolerability, the Bruton’
Autor:
George A Follows, Andreas Pircher, Barbara Ferstl, Carsten Müller-Tidow, Sascha Dietrich, Monika Ebnöther, Claire Dearden, Clemens-Martin Wendtner, Anthony D. Ho, Tobias Roider, Thorsten Zenz, Isabella Haberbosch, Jan-Paul Bohn, Xavier Troussard, Peter Dreger, Nora Liebers
Publikováno v:
Leukemia. 34:1454-1457
Autor:
Jan-Paul Bohn, Sascha Dietrich
Publikováno v:
Cancers. 14(4)
Classic hairy cell leukemia (HCL) is a rare indolent B-cell lymphoproliferative disorder characterized by profound pancytopenia and frequent infectious complications due to progressive infiltration of the bone marrow and spleen. Lacking effective tre